A significant setback in clinical trials led to a sharp decline in argenx NV ADR's stock value.
Shares of argenx NV ADR (NASDAQ:ARGX) fell dramatically yesterday, closing down 11.83%. This drop was mainly due to the company's announcement that it would discontinue a late-stage clinical trial for its autoimmune drug, Vyvgart, following recommendations from an independent committee.
Investor takeaway: Investors should be cautious as the discontinuation of the trial not only affects potential revenue but also raises concerns about the company's pipeline and future growth prospects.
Advertisement
argenx NV ADR
ARGX.US
ARGX.US
argenx NV ADR
WealthAwesomeMarket cap
$58.39B
P/E
35.4x
52W high
$1072.75
52W low
$661.85
1W change
-12.54%
Beta
-0.04
Analyst Price Targets
Based on 11 analysts covering ARGX · as of Oct 5, 2026
Wall Street analysts forecast ARGX stock price to rise 44.2% over the next 12 months.
Consensus
Buy4.45 / 5.00
Avg. Target
C$1180.26
+44.2% Upside
Previously C$1180.17 on Oct 1, 2026
Current Price
C$818.63
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ARGX's historical volatility
30-Day Vol
42.3%
Annualized
90-Day Vol
47.9%
Annualized
Trend (90d)
-22.1%
Annualized drift
90d Mean
C$756.41
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$797.34 | C$689.17 – C$922.49 |
| 60 trading days | C$776.60 | C$631.91 – C$954.44 |
| 90 trading days | C$756.41 | C$587.60 – C$973.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
$3.5 billion
The discontinuation of the trial erased a potential $3.5 billion opportunity for argenx, highlighting the financial implications of clinical setbacks.
Bull case
Despite this setback, argenx has a solid product pipeline and established partnerships that could still drive future growth.
Bear case
The halted trial represents a significant loss of potential revenue, estimated at $3.5 billion, which could negatively impact investor sentiment and stock performance in the near term.
Advertisement
The Impact of the Discontinued Trial
The decision to halt the clinical trial for Vyvgart has sent shockwaves through the market, as it was expected to be a significant revenue driver for argenx. The independent committee's recommendation raises questions about the drug's efficacy and safety, leading to a loss of investor confidence.
Market Reaction and Future Outlook
The stock's sharp decline reflects broader concerns within the healthcare sector, which has seen a downturn in recent trading sessions. Investors are now closely monitoring argenx's remaining pipeline and partnerships to gauge the company's ability to recover from this setback.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
